Stéphane D. B.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 1 Dose Escalation Study of SGR-2921 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Phase 1 Dose-Escalation Study of CC-96191 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 146 of 277 partner sites.
Specializations
Primary Research Focus
This investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on developing novel therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Targeted Therapies
- Mutation-Specific Treatments
- Combination Therapy Approaches
Their work extensively covers innovative treatments targeting specific genetic mutations including IDH1, IDH2, and FLT3-ITD variants in AML.
Secondary Research Areas
The investigator conducts research in related hematologic conditions, including myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML).
- High-Risk MDS Treatment
- Blast Crisis Management
- Novel Drug Combinations
Their research includes investigating treatments for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced hematologic malignancies.
Therapeutic Innovation
The investigator focuses on evaluating cutting-edge therapeutic agents including menin-MLL inhibitors and mRNA degraders.
- First-in-Human Studies
- Maintenance Therapy Development
- Biomarker-Driven Treatment
Their work encompasses both monotherapy and combination approaches with established agents like azacitidine and venetoclax.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.